Northern Trust Corp Purchases New Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Northern Trust Corp purchased a new stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 11,170 shares of the biotechnology company’s stock, valued at approximately $149,000. Northern Trust Corp owned 0.19% of Atara Biotherapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ATRA. Staley Capital Advisers Inc. increased its position in shares of Atara Biotherapeutics by 25.0% during the fourth quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $666,000 after buying an additional 10,000 shares during the period. Geode Capital Management LLC increased its position in shares of Atara Biotherapeutics by 17.2% during the fourth quarter. Geode Capital Management LLC now owns 54,744 shares of the biotechnology company’s stock valued at $729,000 after buying an additional 8,024 shares during the period. Marshall Wace LLP purchased a new position in shares of Atara Biotherapeutics during the fourth quarter valued at about $332,000. Finally, Birchview Capital LP purchased a new position in shares of Atara Biotherapeutics during the fourth quarter valued at about $293,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Performance

Shares of ATRA opened at $8.39 on Wednesday. The stock has a market cap of $50.01 million, a PE ratio of -0.33 and a beta of 0.30. Atara Biotherapeutics, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $18.71. The firm’s 50-day simple moving average is $6.78 and its two-hundred day simple moving average is $8.86.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of ($3.07) by $6.57. The business had revenue of $98.10 million during the quarter, compared to analysts’ expectations of $4.30 million. Equities research analysts predict that Atara Biotherapeutics, Inc. will post -10.39 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group restated a “buy” rating and issued a $17.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $17.75.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.